Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Betting on a widespread GLP-1 adoption, some private equity investors are practicing an investor version of the Ozempic diet and are refraining from investing in consumer companies (such as snackmakers, alcohol brands, or restaurant chains) that could be negatively impacted by the GLP-1 boom, believing that profits will get squeezed as GLP-1 users no longer crave them and/or obesity rates fall
Despite these promising findings, current evidence remains largely preclinical
It still circulates
10.1104/pp.18.01083 Plant Physiol
Food and Drug Administration's list of drugs currently in shortage, though Novo Nordisk, which makes both Wegovy and Ozempic, has said it's working hard to boost production
US$ 25.88
US$ 27.88
US$ 25.77
US$ 23.67
US$ 20.45
US$ 27.66
